However, BACE1 inhibitor clinical trials have been failing to show beneficial cognitive outcomes first in patients with mild‐to‐moderate AD4, 5 and more recently in those with early stages of mild AD or amnesic mild cognitive impairment (MCI) due to AD (prodromal AD).6, 7, 8. This evidence concerns the gene BACE1 and Alzheimer disease.